Klothonova has completed a GMP-grade master cell bank of cells engineered to overexpress α-Klotho protein, positioning an encapsulated cell therapy approach for clinical development. This advancement represents a critical manufacturing milestone for a therapeutic strategy targeting systemic aging through restoration of circulating Klotho levels.
Key Points
- Master cell bank completed and entering viral testing phase
- Encapsulated cell therapy designed to restore circulating α-Klotho protein
- Program targets kidney disease, neurodegeneration, and vascular aging
Longevity Analysis
α-Klotho functions as a systemic coordinator across multiple regulatory pathways—influencing how the body manages mineral balance, vascular function, neurological signaling, and cellular energy production. By engineering cells to produce elevated Klotho, this approach addresses a fundamental aging mechanism rather than treating individual downstream diseases. The progression from cell bank completion to regulatory readiness indicates that protein-replacement strategies, delivered through living cell therapies, are moving from concept to implementation in the clinical timeline.
Original published by Longevity.Technology.